Clinical Scorecard: FDA approves quarterly siRNA for myasthenia gravis
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: FDA approves quarterly siRNA for myasthenia gravis
Key Mechanisms
Mechanisms or clinical associations described in the source article.
Target Population
Population described in the source article.
Care Setting
Cemdisiran is administered subcutaneously by a health care provider every 3 months and is available only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program.
Key Highlights
Cemdisiran (Livsayis) is the first siRNA therapy approved for gMG and the only FDA-approved gMG treatment with quarterly subcutaneous dosing, according to the company.
In the phase 3 NIMBLE trial primary analysis population, the week-24 MG-ADL score improved by 4.5 points with cemdisiran and 2.2 points with placebo; the placebo-adjusted difference was 2.3 points.
At least a 3-point MG-ADL improvement occurred in 76.6% of cemdisiran-treated patients and 44.1% of placebo-treated patients.
QMG scores improved by 4.2 points with cemdisiran and 1.5 points with placebo; the placebo-adjusted improvement was 2.8 points. At least a 5-point QMG improvement occurred in 48.4% and 19% of patients, respectively.
Regeneron reported improvements beginning within 2 weeks and maintained through 24 weeks.
The prescribing information includes a boxed warning for serious meningococcal infections and requires access through a restricted REMS program.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
The prescribing information warns about serious meningococcal infection and other serious infections associated with reduced complement activity.
Reported adverse reactions included injection-site reactions, viral infections, and urinary tract infections.
Risks
Patient & Prescribing Data
Cemdisiran is given at 567 mg subcutaneously every 3 months by a health care provider. FDA approval was supported by the randomized, double-blind, placebo-controlled phase 3 NIMBLE trial of 284 patients, which evaluated cemdisiran alone, a C5-inhibiting monoclonal antibody alone, the combination, or placebo.
Clinical Best Practices
Confirm meningococcal vaccination is up to date and given at least 2 weeks before treatment when possible.
Use antibacterial prophylaxis when urgent treatment is required and the patient is not up to date with meningococcal vaccination.
Follow the restricted REMS program and do not initiate treatment during an unresolved serious Neisseria meningitidis infection.